

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5236013

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	ACEA BIOSCIENCES, INC.	06/19/2018
RECEIVING PARTY DATA		
Name:	ACEA THERAPEUTICS, INC.	
Street Address:	6779 MESA RIDGE ROAD,SUITE 100	
City:	SAN DIEGO	
State/Country:	CALIFORNIA	
Postal Code:	92121	
PROPERTY NUMBERS Total: 36		
Property Type	Number	
Patent Number:	7622507	
Patent Number:	8334316	
PCT Number:	US2005013474	
Patent Number:	8252822	
PCT Number:	US2008070348	
Patent Number:	7851657	
Application Number:	13031134	
PCT Number:	US2011025550	
PCT Number:	US2012021144	
Application Number:	13740182	
PCT Number:	US2013021338	
Patent Number:	9034885	
Patent Number:	8685988	
Application Number:	15708024	
Patent Number:	9763949	
Application Number:	15435722	
Patent Number:	9586965	
Patent Number:	9464089	
Application Number:	15271124	
Application Number:	15882924	

PATENT

Property Type	Number
PCT Number:	US2014046442
Application Number:	60564151
Application Number:	60950191
Application Number:	60950197
Application Number:	60950196
Application Number:	60950181
Application Number:	61306416
Application Number:	61314510
Application Number:	61432164
Application Number:	61586718
Application Number:	61670101
Application Number:	61680231
Application Number:	61814147
Application Number:	61800616
Application Number:	61845342
Application Number:	61923179

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 415-683-5472

Email: eofficeaction@appcoll.com

Correspondent Name: RIMON, P.C.

Address Line 1: ONE EMBARCADERO CENTER, SUITE 400

Address Line 4: SAN FRANCISCO, CALIFORNIA 94111

ATTORNEY DOCKET NUMBER: 4565-2800100

NAME OF SUBMITTER: PENG CHEN

SIGNATURE: /Peng Chen/

DATE SIGNED: 11/14/2018

Total Attachments: 18

source=Entity to Entity Assignment - ACEA Biosciences to Acea Therapeutics_signed#page1.tif
source=Entity to Entity Assignment - ACEA Biosciences to Acea Therapeutics_signed#page2.tif
source=Entity to Entity Assignment - ACEA Biosciences to Acea Therapeutics_signed#page3.tif
source=Entity to Entity Assignment - ACEA Biosciences to Acea Therapeutics_signed#page4.tif
source=Entity to Entity Assignment - ACEA Biosciences to Acea Therapeutics_signed#page5.tif
source=Entity to Entity Assignment - ACEA Biosciences to Acea Therapeutics_signed#page6.tif
source=Entity to Entity Assignment - ACEA Biosciences to Acea Therapeutics_signed#page7.tif
source=Entity to Entity Assignment - ACEA Biosciences to Acea Therapeutics_signed#page8.tif
source=Entity to Entity Assignment - ACEA Biosciences to Acea Therapeutics_signed#page9.tif
source=Entity to Entity Assignment - ACEA Biosciences to Acea Therapeutics_signed#page10.tif

source=Entity to Entity Assignment - ACEA Biosciences to Acea Therapeutics_signed#page11.tif
source=Entity to Entity Assignment - ACEA Biosciences to Acea Therapeutics_signed#page12.tif
source=Entity to Entity Assignment - ACEA Biosciences to Acea Therapeutics_signed#page13.tif
source=Entity to Entity Assignment - ACEA Biosciences to Acea Therapeutics_signed#page14.tif
source=Entity to Entity Assignment - ACEA Biosciences to Acea Therapeutics_signed#page15.tif
source=Entity to Entity Assignment - ACEA Biosciences to Acea Therapeutics_signed#page16.tif
source=Entity to Entity Assignment - ACEA Biosciences to Acea Therapeutics_signed#page17.tif
source=Entity to Entity Assignment - ACEA Biosciences to Acea Therapeutics_signed#page18.tif

ENTITY TO ENTITY ASSIGNMENT

This Assignment is by:

Assignor: ACEA Biosciences, Inc.
Address: 6779 Mesa Ridge Road, Suite 100
San Diego, California 92121

A juristic entity duly organized under and pursuant to the laws of: United States of America

(referred to in this Assignment as "Assignor"), WHEREAS said Assignor is the sole and exclusive owners by assignment of the inventions described and claimed in the patents and patent applications, the serial numbers of which are listed on Exhibit A, attached hereto; and

This Assignment is to:

Assignee: ACEA Therapeutics, Inc.
Address: 6779 Mesa Ridge Road, Suite 100
San Diego, California 92121

A juristic entity duly organized under and pursuant to the laws of: United States of America

(referred to in this Assignment as "Assignee"), which desires to acquire the entire right, title and interest in, to and under said patents and patent applications and the inventions covered thereby.

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,

Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to the above-mentioned inventions, application for letters patent, and any and all provisionals, non-provisionals, divisions, continuations, and continuations-in part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, and any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

Assignor represents, warrants and covenants (a) that, at the time of execution and delivery of this agreement, Assignor is the sole and lawful owner of the entire right, title and interest in and to said inventions and said applications for letters patent, and that the same are unencumbered and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement, or (b) that Assignor was the sole and lawful owners of the entire right, title and interest in and to said inventions and said application for letters patent, and that the same were unencumbered and that Assignor sold, assigned, transferred and set over, to Assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to said inventions and said applications for letters patent.

Assignor shall promptly sign and execute all papers and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to

secure title thereto to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said inventions, or said application for letters patent; (b) any provisional, non-provisional, division, continuation, or continuation-in-part claiming priority thereto or the benefit thereof; or any substitution of any such application; (c) any letters patent or patents for said inventions in any country or jurisdiction, including without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding. For purposes of this paragraph, "procurement, maintenance, enforcement, defense" shall include, without limitation, any preparation, prosecution, pre-grant proceeding, and post-grant proceeding, whether before a patent office or other administrative body or judicial body with jurisdiction therefor.

Assignor hereby authorizes and requests the Commissioner of Patents in the United States to issue the above mentioned letters patent of the United States to Assignee as the assignee of said inventions and the letters patent to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.


Assignor hereby grants Assignee's attorneys, all of Rimon, P.C., the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.

This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR:

Date: 6/19/2018

Signature: 


Name:

Title:

Company: ACEA Biosciences, Inc.

ASSIGNEE:

Date: June 15, 2018

Signature: 

Name:

Title:

Company: ACEA Therapeutics, Inc.

EXHIBIT A

The patents and applications that are being assigned from ACEA Biosciences, Inc. to ACEA Therapeutics, Inc. are:

Application No.	Patent No.	Filing/Issue Date	Title
US 11/110,203	US 7,622,507	11-24-2009	SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF
US 12/368,206	US 8,334,316	12-18-2012	SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF
PCT/US2005/013474		04-20-2005	SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF
CA 2562065	CA 2562065	06-28-2016	SUBSTITUTED ORGANO-SULFUR COMPOUNDS AND METHODS OF USING THEREOF
EP 057793010	EP 1742635	04-20-2005	SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF
IN 2888KOLNP2006	IN 251939	04-18-2012	SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF
JP 2007509600	JP 5004790	06-01-2012	SUBSTITUTED ORGANO-SULFUR COMPOUNDS AND METHODS OF USING

Application No.	Patent No.	Filing/Issue Date	Title
			THEREOF
JP 2011112874		04-20-2005	SUBSTITUTED ORGANO-SULFUR COMPOUNDS AND METHODS OF USING THEREOF
DE 057793010		04-20-2005	SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF
ES 057793010		04-20-2005	SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF
FR 057793010		04-20-2005	SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF
GB 057793010		04-20-2005	SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF
IT 057793010		04-20-2005	SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF
US 12/175,154	US 8,252,822	08-28-2012	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
PCT/US2008/070348		07-17-2008	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
CA 2693162	CA 2693162	05-16-2017	HETEROCYCLIC

Application No.	Patent No.	Filing/Issue Date	Title
			COMPOUNDS AND USES AS ANTICANCER AGENTS
EP 088272323	EP 2188271	01-11-2017	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
IN 561KOLNP2010		07-17-2008	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
JP 2010517163	JP 5457344	01-17-2014	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
DE 088272323	DE 6020080483835	01-11-2017	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
ES 088272323		01-11-2017	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
FR 088272323		01-11-2017	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
GB 088272323		01-11-2017	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
IT 088272323	IT 5020170000384 85	01-11-2017	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
EP 171508518		07-17-2008	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
US 12/413,385	US 7,851,657	12-14-2010	SYNTHETIC PROCESS FOR ANTICANCER DRUG FLUORAPACIN AND TRISULFIDE DERIVATEVES
US 13/031,134		02-18-2011	HETEROCYCLIC

Application No.	Patent No.	Filing/Issue Date	Title
			COMPOUNDS AND USES AS ANTICANCER AGENTS
PCT/US2011/025550		02-18-2011	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
CA 2789249		02-18-2011	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
CN 2011800185498		02-18-2011	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
EP 117061234		02-18-2011	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
IN 7165CHENP2012		02-18-2011	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
JP 2012554073		02-18-2011	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
RU 2012140020		02-18-2011	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
BR 1120120205528		02-18-2011	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
HK 131068609		02-18-2011	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
PCT/US2012/021144		01-12-2011	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
US 13/740,182		01-12-2013	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS

Application No.	Patent No.	Filing/Issue Date	Title
PCT/US2013/021338		01-12-2013	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
AU 2013207712	AU 2013207712	12-18-2017	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
CA 2861010		01-12-2013	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
CN 2013800132790		01-12-2013	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
EP 137013264		01-12-2013	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
JP 2014552357		01-12-2013	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
HK 151042840		01-12-2013	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
US 13/843,554	US 9,034,885	05-19-2015	NOVEL EGFR MODULATORS AND USES THEREOF
US 13/917,514	US 8,685,988	04-01-2014	NOVEL EGFR MODULATORS AND USES THEREOF
US 15/708,024		09-18-2017	NOVEL EGFR MODULATORS AND USES THEREOF
US 14/712,794	US 9,763,949	09-19-2017	NOVEL EGFR MODULATORS AND USES THEREOF
US 15/435,722		02-17-2017	NOVEL PYRROLOPYRIMIDINE

Application No.	Patent No.	Filing/Issue Date	Title
			COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
US 14/420,341	US 9,586,965	03-07-2017	PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
PCT/US2013/050163		07-11-2013	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
CN 2013800013594	ZL2013800013594	10-20-2017	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
AU 2013300106		07-11-2013	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
BR 1120150027091		07-11-2013	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
CA 2881275		07-11-2013	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
EP 137454914	EP 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES

Application No.	Patent No.	Filing/Issue Date	Title
IN 914DELNP2015		07-11-2013	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
IL 237023		07-11-2013	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
JP 2015526540	JP 6215938	09-29-2017	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
KR 1020157006007		07-11-2013	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
NZ 629807	NZ 629807	08-01-2017	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
RU 2015107831		07-11-2013	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
SG 11201500872S	SG 11201500872S	03-28-2017	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
ZA 201500762		07-11-2013	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES

Application No.	Patent No.	Filing/Issue Date	Title
TR 1501356		07-11-2013	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
MXA2015001715		07-11-2013	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
ZA 201600647		07-11-2013	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
HK 151112827		07-11-2013	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
ZA 201600648		07-11-2013	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	AL 6611	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	AT 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	BE 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	BG 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN

Application No.	Patent No.	Filing/Issue Date	Title
			KINASES
	CH 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	CY 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	CZ 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	DE 6020130150478	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
DK 137454914	DK 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
EE 137454914		12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
ES 137454914		12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	FI 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES

Application No.	Patent No.	Filing/Issue Date	Title
	FR 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	GB 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	GR 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	HR 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	HU 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	IE 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	IS 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	IT 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES

Application No.	Patent No.	Filing/Issue Date	Title
LT 2880035		12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
LU 2880035		12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	LV 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	MC 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	MK 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
MT 2880035		12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	NL 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
NO 137454914		12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES

Application No.	Patent No.	Filing/Issue Date	Title
PL 137454914		12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
PT 137454914	PT 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
RO 137454914	RO 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	RS 55746	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	SE 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	SI 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	SK 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	SM 2880035	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
	TR201703089T4	12-07-2016	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN

Application No.	Patent No.	Filing/Issue Date	Title
			KINASES
EP 162023410		07-11-2013	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
JP 20175935		07-11-2013	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
CN 2017102293087		07-11-2013	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
HK 17112259.2		07-11-2013	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
US 14/329,890	US 9,464,089	10-11-2016	HETEROCYCLIC COMPOUNDS AND USES THEREOF
US 15/271,124		09-20-2016	HETEROCYCLIC COMPOUNDS AND USES THEREOF
US15/882,924		01-29-2018	HETEROCYCLIC COMPOUNDS AND USES THEREOF
PCT/US2014/046442		07-11-2014	HETEROCYCLIC COMPOUNDS AND USES THEREOF
AU 2014287016		07-11-2014	HETEROCYCLIC COMPOUNDS AND USES THEREOF
BR1120160001958		07-11-2014	HETEROCYCLIC COMPOUNDS AND USES THEREOF

Application No.	Patent No.	Filing/Issue Date	Title
CA 2917364		07-11-2014	HETEROCYCLIC COMPOUNDS AND USES THEREOF
CN 2014800497934		07-11-2014	HETEROCYCLIC COMPOUNDS AND USES THEREOF
EP 147483515		07-11-2014	HETEROCYCLIC COMPOUNDS AND USES THEREOF
HK 161114904		07-11-2014	HETEROCYCLIC COMPOUNDS AND USES THEREOF
IL 243420		07-11-2014	HETEROCYCLIC COMPOUNDS AND USES THEREOF
IN 201617004306		07-11-2014	HETEROCYCLIC COMPOUNDS AND USES THEREOF
JP 2016525833		07-11-2014	HETEROCYCLIC COMPOUNDS AND USES THEREOF
KR 1020167002970		07-11-2014	HETEROCYCLIC COMPOUNDS AND USES THEREOF
MXA2016000261		07-11-2014	HETEROCYCLIC COMPOUNDS AND USES THEREOF
NZ 715687		07-11-2014	HETEROCYCLIC COMPOUNDS AND USES THEREOF
RU 2016104388		07-11-2014	HETEROCYCLIC COMPOUNDS AND USES THEREOF
SG 11201600062R		07-11-2014	PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS
ZA 201600148		07-11-2014	HETEROCYCLIC COMPOUNDS AND USES THEREOF
ZA 201700221		07-11-2014	HETEROCYCLIC COMPOUNDS AND USES THEREOF

Application No.	Patent No.	Filing/Issue Date	Title
RU 2015107831		07-11-2013	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
US 60/564,151		04-20-2004	SUBSTITUTED ORGANO SULFUR ANALOGUES AND THEIR USES FOR TREATMENT OR PREVENTION OF TUMORS
US 60/950,191		07-17-2007	THIAZOLE-SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS AND USES FOR CANCER TREATMENT
US 60/950,197		07-17-2007	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
US 60/950,196		07-17-2007	TETHERED HETEROCYCLIC COMPOUNDS AND METHODS OF USING THEREOF
US 60/950,181		07-17-2007	SUBSTITUTED DIHYDROTRIAZOLOPYRI MIDINE DERIVATIVES AND USES AS ANTICANCER AGENTS
US 61/306,416		02-19-2010	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
US 61/314,510		03-16-2010	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
US 61/432,164		01-12-2011	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
US 61/586,718		01-13-2012	HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
US 61/670,101		07-10-2012	HETEROCYCLIC COMPOUNDS AND USES THEREOF

Application No.	Patent No.	Filing/Issue Date	Title
US 61/680,231		08-06-2012	NOVEL EGFR MODULATORS AND USES THEREOF
US 61/814,147		04-19-2013	NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
US 61/800,616		03-15-2013	BICYCLIC HETEROARYL COMPOUNDS AS EGFR MODULATORS
US 61/845,342		07-11-2013	HETEROCYCLIC COMPOUNDS AND USES THEREOF
US 61/923,179		01-02-2014	HETEROCYCLIC COMPOUNDS AND USES THEREOF